Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Trial Profile

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
    • 03 Nov 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2020.
    • 12 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top